Related Experiment Video
Updated: Apr 15, 2026
11:50
Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines
Published on: September 10, 2014
14.0K
Secondary Cytoreduction in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Institution Experience
A Musella1, C Marchetti2, I Palaia2
1Department of Gynecological and Obstetrical Sciences and Urological Sciences, "Sapienza" University of Rome, Rome, Italy. angela.musella@gmail.com.
Annals of Surgical Oncology
|March 25, 2015
Summary
Secondary cytoreductive surgery significantly improves overall survival in carefully selected patients with platinum-resistant recurrent ovarian cancer (OC). This approach offers a survival benefit compared to chemotherapy alone for ovarian cancer management.
Area of Science:
- Gynecologic Oncology
- Surgical Oncology
- Medical Oncology
Background:
- Platinum-resistant recurrent ovarian cancer (OC) presents a significant clinical challenge.
- Identifying effective treatment strategies for this patient population is crucial.
Purpose of the Study:
- To evaluate the role and efficacy of secondary cytoreductive surgery in patients with platinum-resistant recurrent ovarian cancer.
- To compare outcomes between patients undergoing secondary cytoreductive surgery and those treated with chemotherapy alone.
Main Methods:
- Retrospective analysis of 122 platinum-resistant recurrent OC patients treated between 1995 and 2013.
- Inclusion criteria focused on specific patient characteristics and treatment history.
- Comparison of 18 surgically treated patients (Group A) with 18 matched controls not eligible for surgery (Group B).
Main Results:
- Secondary cytoreductive surgery was associated with a significantly longer overall survival (P = 0.035).
- Median overall survival was 44 months.
- Estimated 5-year overall survival rates were 57% for the surgical group versus 23.5% for the control group.
Conclusions:
- Secondary cytoreductive surgery can be a valuable addition to chemotherapy for carefully selected platinum-resistant recurrent OC patients.
- Highly specialized centers are recommended for performing this procedure.
- Further prospective trials are warranted to validate these findings.
More Related Videos
Related Concept Videos
02:56Treatment Resistent Cancers
1.5K
1.5K
02:56Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K